Brief: Atyr Pharma Announces Scheduling Of FDA Type C Meeting To Discuss Efzofitimod Program In Pulmonary Sarcoidosis
03/02/2026 13:25
Feb 3 (Reuters) - aTyr Pharma Inc ATYR.O: ATYR PHARMA ANNOUNCES SCHEDULING OF FDA TYPE C MEETING TO DISCUSS EFZOFITIMOD PROGRAM IN PULMONARY SARCOIDOSIS ATYR PHARMA INC - TYPE C MEETING SCHEDULED FOR MID-APRIL 2026 Source text: ID:nGNX32WNDX Further company coverage: ATYR.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on aTyr Pharma
See all newsBrief: Atyr Pharma Announces Research Collaboration With Montefiore Einstein
U.S. STOCKS ON THE MOVE-Charles River, Oracle, TD Synnex
US STOCKS ON THE MOVE-Charles River, Oracle, TD Synnex
U.S. STOCKS ON THE MOVE-CoreWeave, Versant Media, BlackBerry
aTyr rises as FDA aligns on late-stage lung disease study plan